Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 14;9(1):11832.
doi: 10.1038/s41598-019-48388-7.

Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson's disease

Affiliations

Inner retinal thinning as a biomarker for cognitive impairment in de novo Parkinson's disease

Mi Sun Sung et al. Sci Rep. .

Abstract

We investigated the association between retinal changes measured using optical coherence tomography (OCT) and diverse clinical grading scales in patients with Parkinson's disease (PD). Seventy-four eyes of 74 patients with de novo PD and 53 eyes of age-matched control subjects were included. The thickness of the peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell-inner plexiform layer (mGCIPL) were measured. We analyzed the correlations between the clinical PD grading scales and OCT parameters, and between the OCT parameters and volumetric data in the cerebral cortical and subcortical structures. The area under the receiver operating characteristic curve (AUC) was calculated for diagnosing cognitive impairment in patients with PD. Statistically significant reductions in the thickness of average, temporal, and inferior pRNFL and overall mGCIPL were observed in patients with PD. The Montreal Cognitive Assessment score was significantly associated with mGCIPL thinning. The AUC of the mGCIPL parameters for diagnosing cognitive impairment in patients with PD ranged from 0.651 to 0.760. Moreover, thinning of the mGCIPL was significantly associated with the volumetric parameters of associated brain structures. Our findings highlight the clinical implications of OCT measurements as a potential biomarker for early detection of cognitive impairment in patients with PD.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Comparison of the mGCIPL thickness between the patients with PD who had a normal cognition (PD-NC) and those with a cognitive impairment (PD-CI). PD = Parkinson’s disease; mGCIPL = macular ganglion cell-inner plexiform layer.
Figure 2
Figure 2
ROC curves and AUC values of the mGCIPL thickness parameters for detection of cognitive impairment in patients with PD. ROC = receiver operating characteristic; AUC = area under the ROC curve; mGCIPL = macular ganglion cell-inner plexiform layer; PD = Parkinson’s disease.

References

    1. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol. 2012;124:325–338. doi: 10.1007/s00401-012-1013-5. - DOI - PMC - PubMed
    1. Visser M, et al. A comprehensive model of health-related quality of life in Parkinson’s disease. J Neurol. 2008;255:1580–1587. doi: 10.1007/s00415-008-0994-4. - DOI - PubMed
    1. Litvan I, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26:1814–1824. doi: 10.1002/mds.23823. - DOI - PMC - PubMed
    1. London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44–53. doi: 10.1038/nrneurol.2012.227. - DOI - PubMed
    1. Patton N, et al. The association between retinal vascular network geometry and cognitive ability in an elderly population. Invest Ophthalmol Vis Sci. 2007;48:1995–2000. doi: 10.1167/iovs.06-1123. - DOI - PubMed

Publication types